 Cue Biopharma, Inc. CUE, a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body, announced today a poster presentation featuring pre-clinical data on CUE-102A02 and CUE-102A24, the companys second and third drug candidates from the CUE-100 series at the American Association for Cancer Research AACR Virtual Annual Meeting II. CUE-102 biologics are Immuno-STATsTM Selective Targeting and Alteration of T cells designed to selectively target and expand Wilms tumor 1 WT1 specific T cells for the treatment of patients with solid and hematological cancers. 